SCHEMBL24328889

SCHEMBL24328889

CO[C@@H](C(=O)O)c1ccc(F)cn1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APLNR P35414 2/20 0.44
KDM4E B2RXH2 1/20 0.35
NPC1 O15118 1/20 0.35
LMNA P02545 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
KMO O15229 2/20 0.35
ALDH1A1 P00352 2/20 0.35
GAA P10253 1/20 0.35
GRM5 P41594 1/20 0.34
KMT2A Q03164 2/20 0.33
MEN1 O00255 1/20 0.33
FABP4 P15090 1/20 0.33
FABP5 Q01469 1/20 0.33
MAPT P10636 1/20 0.33
CXCR2 P25025 2/20 0.33
CXCR1 P25024 1/20 0.33
FFAR2 O15552 1/20 0.33
IDO1 P14902 1/20 0.32
TDO2 P48775 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24327747 1.00 APLNR (0.44) APLNRKDM4ENPC1LMNARAB9A
SCHEMBL22295286 0.80 APLNR (0.40) APLNRKDM4ENPC1LMNARAB9A
SCHEMBL24328887 0.80 CACNA1I (0.43) SMN1; SMN2ALDH1A1
SCHEMBL24327743 0.80 CACNA1I (0.43) SMN1; SMN2ALDH1A1
SCHEMBL17765226 0.77 APLNR (0.51) APLNRLMNAKMOKMT2AMEN1
SCHEMBL17765315 0.77 APLNR (0.46) APLNRNPC1KMOGRM5FFAR2
SCHEMBL26942630 0.76 APLNR (0.40) APLNRLMNASMN1; SMN2ALDH1A1GAA
SCHEMBL25581873 0.75 APLNR (0.49) APLNRKMOGRM5
SCHEMBL15709789 0.75 APLNR (0.45) APLNRALDH1A1GAAGRM5KMT2A
SCHEMBL158994 0.74 APLNR (0.44) APLNRNPC1KMOFFAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230399297-A1 Novel Glutamine Analogs JACOBIO PHARMACEUTICALS CO., LTD (CN) 2023-12-14 US disclosed
US-20230399297-A1 Novel Glutamine Analogs JACOBIO PHARMACEUTICALS CO., LTD (CN) 2023-12-14 US disclosed
WO-2022078416-A1 NOVEL GLUTAMINE ANALOGS JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2022-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230399297-A1 Novel Glutamine Analogs GLUL, GATD3, GLS APLNR 658/4885KDM4E 1022/4885NPC1 4231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.